An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

• Main Authors: A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin
• Format: Article
• Language: Russian
• Published: Izdatelstvo OKI 2019-04-01
• Series: Качественная клиническая практика
• Subjects: breast cancer; trastuzumab emtanzine; cost-effectiveness analysis; pharmacoeconomics; budget impact analysis
• Online Access: https://www.clinvest.ru/jour/article/view/424

Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoeconomic evaluation of T-DM1 in patients with HER2+ breast cancer (BC) and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis were performed. Direct medical costs and indirect costs (GDP loss) were accounted. Results. At 5 years modeling horizon total cost of trastuzumab emtanzine were higher comparing to lapatinib+capecitabine due to significantly higher overall survival (OS) observed in T-DM1 group. CER OS for T-DM1 was by 21% lower comparing to CER lapatinib+capecitabine (2 099 940 RUR/patient/year and 2 541 879 RUR/patient/year, consequently). Conclusions. The study showed T-DM1 is a cost-effective strategy in patient with HER2+ metastatic BC and CNS metastases.